The company's platform focuses on developing stroke prevention and anti-thrombosis drugs based on Factor XI, an enzyme in the blood coagulation pathway. These drugs are designed to prevent thrombosis without causing excessive bleeding, allowing physicians to treat serious consequences such as venous thromboembolism, deep vein thrombosis, stroke, and heart attack. Founded in 2012 and headquartered in Westborough, Massachusetts, ExIthera Pharmaceuticals serves clients in the healthcare sector.